The ascendancy of Viagra and its impact on the pharmaceutical landscape presents a intricate question for shareholders. While the initial sales figures were impressive, the intellectual property has ended, leading to a deluge of off-brand alternatives that are chipping away at revenue. read more In addition, the market is facing challenges related